University of Michigan, Ann Arbor, MI
Cindy Jiang, Garth William Strohbehn, Rachel Dedinsky, Shelby Raupp, Brittany Pannecouk, Sarah Elizabeth Yentz, Nithya Ramnath
Background: There was rapid adoption of teleoncology at Veterans Health Administration (VHA) during the COVID-19 pandemic. One-third of 9 million VHA-enrolled Veterans live in rural areas. While digital solutions can expand capacity, enhance care access, and reduce financial burden, they may also exacerbate rural-urban health disparities. Careful evaluation of patients’ perceptions and policy tradeoffs are necessary to optimize teleoncology post-pandemic. Methods: Patients with ≥1 teleoncology visit with medical, surgical, or radiation oncology between March 2020 and June 2020 identified retrospectively. Validated, Likert-type survey assessing patient satisfaction developed. Follow-up survey conducted on patients with ≥1 teleoncology visit from August 2020 to January 2021. Travel distance, time, cost, and carbon dioxide (CO2) emissions calculated based on zip codes. Results: 100 surveys completed (response rate, 62%). Table with demographics. Patients overall satisfied with teleoncology (83% ‘Agree’ or ‘Strongly Agree’) but felt less satisfied than in-person visits (47% ‘Agree’ or ‘Strongly Agree’). Audiovisual component improved patient perception of involvement in care (two-sided, p = 0.0254), ability to self-manage health/medical needs (p = 0.0167), and comparability to in person visits (p = 0.0223). Follow-up survey demonstrated similar satisfaction. Total travel-related savings: 86,470 miles, 84,374 minutes, $49,720, and 35.5 metric tons of CO2. Conclusions: Veterans are broadly satisfied with teleoncology. Audiovisual capabilities are critical to satisfaction. This is challenging for rural populations with lack of technology access. Patients experienced financial and time savings, and society benefitted from reduced carbon emissions. Continued optimization needed to enhance patient experience and address secondary effects.
Eligible Pts (n = 366) | Surveyed Pts (n = 100) | Re-Surveyed Pts (n = 42) | |
---|---|---|---|
Age, yrs – Mean (Std. Dev) | 68.7 (9.3) | 68.6 (8.8) | 67.8 (8.3) |
Sex Female – No. (%) Male – No. (%) | 16 (4.4) 350 (95.6) | 5 (5) 95 (95) | 4 (9.5) 38 (90.5) |
Race White – No. (%) Black – No. (%) Hawaiian/Pacific Islander – No. (%) Did not declare (%) | 288 (78.7) 38 (10.4) 6 (1.6) 34 (9.3) | 76 (76) 11 (11) 3 (3) 10 (10) | 32 (76.2) 5 (11.9) 3 (7.1) 2 (4.8) |
Malignancy – No. (%) Bladder Breast CNS Endocrine Gastrointestinal/hepatobiliary Testicular Head and neck Lung Neuroendocrine Prostate Renal Skin and soft tissue | 8 (2.2) 10 (2.7) 1 (0.3) 1 (0.3) 110 (30.1) 3 (0.8) 23 (6.3) 82 (22.4) 9 (2.5) 93 (25.4) 6 (1.6) 20 (5.5) | 2 (2) 4 (4) 0 (0) 0 (9) 23 (23) 0 (0) 4 (4) 18 (18) 4 (4) 29 (29) 3 (3) 9 (9) | 1 (2.4) 2 (4.9) 0 (0) 0 (0) 8 (19) 0 (0) 2 (4.9) 8 (19) 2 (4.9) 15 (35.7) 2 (4.9) 2 (4.9) |
Total # Teleoncology Visits | |||
Visit per pt – Mean (Std. Dev) | 560 | 230 | 76 |
Teleoncology Mode Audio-Only Audiovisual-Only Audio + Audiovisual | 1.53 (0.92) n/a | 2.3 (1.5) 41 (41.0) 40 (40.0) 19 (19.0) | 1.8 11 (26.2) 24 (57.1) 7 (16.7) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Min Jee Lee
2021 ASCO Annual Meeting
First Author: Regan Healy
2023 ASCO Annual Meeting
First Author: Sabrina Wilcox
2021 ASCO Annual Meeting
First Author: Patricia Jewett